Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC

Karen Kelly, MD
Published: Thursday, Aug 25, 2016


Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Much research lies ahead regarding combinations of immunotherapy agents in the field of lung cancer, Kelly explains. However, prior studies in melanoma demonstrate that PD-1 and CTLA-4 inhibitors do demonstrate significant survival benefits when combined. Data reported for nivolumab (Opdivo) and ipilimumab (Yervoy) in NSCLC have shown promise; however, the associated adverse events are concerning.

Practitioners hope that these combinations produce deep, durable responses that translate into prolonged survival. Nevertheless, it is not yet determined whether two-drug combinations will be more effective versus monotherapy with an immune agent, she adds.

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Much research lies ahead regarding combinations of immunotherapy agents in the field of lung cancer, Kelly explains. However, prior studies in melanoma demonstrate that PD-1 and CTLA-4 inhibitors do demonstrate significant survival benefits when combined. Data reported for nivolumab (Opdivo) and ipilimumab (Yervoy) in NSCLC have shown promise; however, the associated adverse events are concerning.

Practitioners hope that these combinations produce deep, durable responses that translate into prolonged survival. Nevertheless, it is not yet determined whether two-drug combinations will be more effective versus monotherapy with an immune agent, she adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x